What factors drove the changes in Tandem Diabetes Care's revenue and profit?

What is Tandem Diabetes Care's latest dividend and current dividend yield?

What were the key takeaways from Tandem Diabetes Care’s earnings call?

What guidance did Tandem Diabetes Care's management provide for the next earnings period?

What is the revenue and EPS growth rate for Tandem Diabetes Care year over year?

What does Tandem Diabetes Care do and what are its main business segments?

Did Tandem Diabetes Care beat or miss consensus estimates last quarter?

What were the key takeaways from Tandem Diabetes Care's earnings call?

- **Record 2025 Performance**: $1.015 billion revenue (+12% YoY), Q4 sales $290 million (+15% YoY)
- **Strategic PayGo Transition**: 20% U.S. pumps via PayGo by end-2026, targeting 70%+ long-term
- **Gross Margin Expansion**: 56-57% in 2026 (vs. 54% in 2025)
- **International Growth**: Direct Europe operations driving 15%+ international sales growth
- **Innovation Pipeline**: Mobi Tubeless FDA submission Q2, fully closed-loop trial planned for 2026

**【CEO Summary Section】**
- Tandem achieved a record $1.015 billion in 2025 revenue, with Q4 sales of $290 million (+15% YoY) driven by 27,000 U.S. pump shipments (+14% YoY) and 11,000 international shipments (+17% YoY). 
- Key 2025 initiatives: 
  1. Commercial modernization: Expanded U.S. sales team, implemented new systems, and launched direct operations in U.K., Switzerland, and Austria
  2. Technology innovation: Launched Control-IQ+ for type 2 diabetes, FreeStyle 3 Plus, and Android control; Mobi Tubeless FDA submission planned for Q2
  3. Business model reshaping: Transitioning to pay-as-you-go (PayGo) in U.S., targeting 20% PayGo pump shipments by end-2026
- 2026 outlook: 10-11% U.S. pump shipment growth, 15%+ international growth, and gross margin expansion to 56-57%

**【CFO Financial Commentary】**
- 2025 financial highlights: 
  - Worldwide sales: $1.015 billion (+12% YoY)
  - Gross margin: 54% (up 3pts YoY)
  - Adjusted EBITDA: $111 million (11% of sales)
  - Free cash flow positive in Q3 and Q4
- 2026 guidance: 
  - Sales: $1.065-1.085 billion (+5-6% YoY)
  - Gross margin: 56-57% (up 2-3pts YoY)
  - Adjusted EBITDA: 5-6% of sales
  - PayGo headwinds: $70-80 million in 2026, offset by 4x+ supply pricing in pharmacy channel
- International expansion: Direct operations in 3 European markets, ASP premiums of 30%+, and $335-340 million international sales (+10-11% YoY)

**【Q&A Highlights】**
- PayGo transition: 
  - 20% of U.S. pumps via PayGo by end-2026, 70%+ long-term
  - Pharmacy supply pricing ~$350/month vs. DME ~$80/month
  - 2026 gross margin expansion driven by pricing, cost reductions, and Mobi scale
- Product pipeline: 
  - Mobi Tubeless FDA approval expected H2-2026
  - Fully closed-loop system pivotal trial planned for 2026
  - SteadiSet extended wear infusion set and Dexcom 15-day sensor integration
- Risk management: 
  - 2026 operating margin negative 2-1% in Q1, positive from Q2
  - Free cash flow neutral in 2026, positive from 2027

Tandem Diabetes Care, Inc. (TNDM) Q4 2025 Earnings Call Transcript

- **Q3 Record Performance**: $249M revenue (+15% YoY), 54% gross margin, and return to positive EBITDA. 
- **Strategic Growth Drivers**: 2026 targets include 60%+ gross margin, 15% direct intl. sales, and Mobi Tubeless launch. 
- **Innovation Momentum**: Mobi Android, t:slim Libre 3 integration, and Type 2 diabetes expansion driving pipeline. 
- **Pharmacy Channel Acceleration**: 5% Q3 pharmacy sales, with t:slim supplies now available and 40% U.S. coverage. 
- **Operational Efficiency**: $3M Q3 restructuring costs to support 2026 margin expansion. 


**【CEO Summary Section】**
- **Record Q3 Sales**: Achieved $249 million, driven by U.S. ASP increases and international growth. Pump shipments met expectations, with September as the strongest month. 
- **Commercial Transformation**: U.S. sales productivity improving; direct European operations launching in 2026 (UK, Switzerland, Austria). 
- **Innovation Highlights**: 
  - Mobi Android app awaiting FDA clearance to expand global addressable market. 
  - t:slim X2 with Abbott FreeStyle Libre 3 Plus integration now fully available in the U.S. 
  - Mobi Tubeless (extended wear patch pump) in final testing stages for 2026 launch. 
- **Type 2 Diabetes Expansion**: Full commercial launch of Control-IQ+ for Type 2 patients, doubling U.S. addressable market. 
- **Pharmacy Channel Growth**: 5% of U.S. sales via pharmacy in Q3, with t:slim supplies now available. Early uptake driven by affordability and convenience. 

**【CFO Financial Commentary】**
- **Q3 Financials**: 
  - Revenue: $249 million (+15% YoY). 
  - Gross Margin: 54% (+3ppt YoY). 
  - Adjusted EBITDA: Returned to positive. 
  - Free Cash Flow: Positive for the quarter. 
- **2025 Guidance**: 
  - Full-year revenue: ~$1 billion (U.S. $700M, international $300M). 
  - Gross margin: 53-54% (Q4 expected to be all-time high in mid-50s). 
  - Adjusted EBITDA: -5% of sales. 
- **2026 Outlook**: 
  - Gross margin target: ≥60% in Q4 2026. 
  - Direct international sales to contribute ~15% of international revenue. 
  - Cost optimization initiatives (e.g., $3M restructuring costs in Q3) expected to yield savings. 

**【Q&A Highlights】**
- **Mobi Tubeless Priority**: 510(k) submission nearing completion; expected to launch ahead of SteadySet. 
- **Pharmacy Channel Dynamics**: 40% of U.S. lives covered by Mobi pharmacy benefit; 2026 focus on scaling supply revenue via t:slim. 
- **Gross Margin Drivers**: ASP increases (+5% YoY in Q3), Mobi cost scaling, and pharmacy channel expansion. 
- **Competitive Position**: Leading in U.S. pump market with >70% renewal capture rate; international end-user placements growing double-digit YoY. 
- **Fully Closed-Loop Progress**: Pivotal study for UVA-developed algorithm planned for 2026. 


Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript

- **$1B Sales Milestone Achievable**: 2025 guidance raised to $1B, driven by U.S. pharmacy channel expansion and OUS direct sales transition.
- **Gross Margin Expansion**: 52% Q2 gross margin, targeting 60% by end-2026 through Mobi scale and pharmacy channel pricing.
- **Type 2 Diabetes Growth**: Pilot territories show 2x adoption rate, with CMS coverage expansion efforts underway.
- **Pharmacy Channel Breakthrough**: t:slim supplies launch Q4 2025, with 30% U.S. insurance coverage and 0 upfront patient cost in pilot contracts.
- **International Risk-Adjusted Growth**: OUS sales up 25% YoY despite $10M annualized headwind, with direct sales preparation on track.

**【CEO Summary Section】**
- **Record Q2 Sales**: Achieved $241M in worldwide sales, driven by U.S. pump shipments and international demand. Mobi platform adoption grew, with 2/3 of new starts converting from MDI therapy.
- **Type 2 Diabetes Expansion**: Piloted type 2 commercial activities, seeing higher adoption in pilot territories. CMS proposal to address insulin pump coverage could expand access for Medicare patients.
- **Pharmacy Channel Progress**: Launched t:slim supplies in the pharmacy channel Q4 2025, aiming to lower patient costs and increase sales through 30%+ U.S. insurance coverage.
- **International Growth**: OUS sales reached $70M, with strong renewals and preparation for direct sales in Europe starting 2026.
- **Product Pipeline**: Submitted Steadiset 510(k) for extended wear infusion sets and plans to launch tubeless Mobi in 2026.

**【CFO Financial Commentary】**
- **Q2 Financials**: Non-GAAP net income of $420M, with 15% YTD sales growth to $475M. U.S. sales up 9% YoY, driven by Mobi adoption and DME channel pricing improvements.
- **Gross Margin Expansion**: 52% gross margin (up 200bps YoY), supported by Mobi cost reductions and pharmacy channel pricing premium.
- **Operating Efficiency**: SG&A expenses grew 10% YoY, but modernized systems and process redesigns will drive back-half savings.
- **Updated Guidance**: Full-year sales target raised to $1B ($700M U.S., $300M OUS), with gross margin expected 53-54% and free cash flow positive in H2.
- **Risks**: CMS Medicare proposals (pay-as-you-go, competitive bidding) could impact <10% of U.S. sales but may expand access long-term.

**【Q&A Key Highlights】**
- **CMS Proposal Impact**: Leigh Vosseller stated <10% of U.S. sales affected, but pay-as-you-go model aligns with pharmacy channel strategy. CMS final ruling expected November 2025.
- **Pharmacy Channel Potential**: 30% U.S. insurance coverage secured, with t:slim supplies launch Q4 2025. Pharmacy sales could add $100M+ in 2026.
- **OUS Headwinds**: $10M annualized headwind from distributor destocking, but strong placements growth (+15% YoY) offsets.
- **Competitive Pressure**: New entrant with large sales force may pause U.S. growth, but Tandem maintains >50% MDI conversion share.
- **Mobi Margins**: Mobi pump cost down 20% YoY, with cartridge margins improving as volumes scale. 60% gross margin target by end-2026.

Tandem Diabetes Care, Inc. (TNDM) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: $234M revenue (+22% YoY), $84M international sales, 15% U.S. growth.
- **Control-IQ+ Expansion**: FDA-cleared for type 2, now covers 300k+ patients, targeting 100%+ market expansion.
- **Profitability Leap**: 51% gross margin (+500bps YoY), 3% EBITDA margin, $370M cash for growth.
- **Pharmacy Channel Breakthrough**: 30% U.S. lives covered, reducing patient costs and driving 10%+ ASP lift.
- **Pipeline Momentum**: Mobi to 60% gross margin by 2026, Sigi in-house with 2027 target, FreeStyle Libre 3 launch Q2.

**【CEO Summary Section】**
- Q1 2025 revenue reached $234 million, up 22% YoY, driven by 15% U.S. sales growth and record international sales of $84 million.
- Launched Control-IQ+ for type 2 diabetes, expanding addressable market by over 100%.
- U.S. pump shipments to new and renewing customers grew, with 2/3 of new starts converting from MDI.
- International renewals began contributing, with 50:50 mix of new and renewing customers.
- Expanded U.S. salesforce and direct European operations to support long-term growth.

**【CFO Financial Commentary】**
- Gross margin improved to 51%, up 500bps YoY, driven by pump cost efficiencies and Mobi scale.
- Adjusted EBITDA margin expanded 5 percentage points YoY to 3% of sales.
- Q1 free cash flow positive, with $370 million in cash to support convertible note repayment.
- 2025 guidance: $997-1.01 billion in sales, 54% gross margin, 3% EBITDA margin.
- Pharmacy channel now covers 30% of U.S. lives, reducing patient out-of-pocket costs and driving long-term profitability.

**【Q&A Highlights】**
- Salesforce expansion complete, with 9-12 months to full productivity; no material disruption from realignment.
- Pharmacy pricing contributed meaningfully in Q1, with 10%+ ASP lift for supplies.
- Control-IQ+ type 2 launch early data shows strong clinical outcomes, with 300k+ patients now eligible.
- Mobi expected to reach 60% gross margin by 2026 as cartridges scale.
- Sigi development accelerated with in-house team, targeting 2027 launch.
- International competition stable, with Tandem holding ~50% market share in key European markets.
- U.S. new starts expected to grow mid-single digits, driven by MDI conversions and Mobi adoption.

Tandem Diabetes Care (TNDM)-30 Apr 25-2025 Q1 Earnings call transcript

- **18% Global Growth**: 2024 sales hit $910M, driven by U.S. and international expansion.
- **Mobi Pump Innovation**: FDA-cleared for Type 2, with 240M patient days of data and 10-15% lower manufacturing costs.
- **Control-IQ+ Expansion**: New features like automated boluses and FDA clearance for Type 2 aged 18+.
- **2025 Financial Targets**: $997-1.01B sales, 54% gross margin, 3% EBITDA margin.
- **Type 2 Opportunity**: Addressable market doubles, with 30,000+ users already on platform.

**【CEO Summary Section】**
- Global sales increased 18% YoY in 2024, driven by U.S. and international growth.
- Launched Mobi pump, a smaller, more wearable platform, which gained 240 million patient days of data and expanded to Type 2 diabetes with FDA clearance.
- Introduced Control-IQ+ algorithm with automated correction boluses and extended bolus features, now cleared for Type 2 patients aged 18+.
- Expanded commercial initiatives including Pharmacy channel access (20% U.S. lives covered) and direct European operations starting 2026.

**【CFO Financial Commentary】**
- 2024 worldwide sales reached $910M (18% YoY growth), with Q4 sales of $252M (20% YoY growth).
- U.S. sales $184M (13% YoY), driven by pump shipments (+10%) and ASP improvements.
- OUS sales $268M (39% YoY), led by t:slim X2 demand.
- Gross margin held steady at 51%, with Mobi manufacturing costs improving.
- 2025 guidance: $997-1.01B sales (10-11% growth), 54% gross margin, 3% EBITDA margin.

**【Q&A Key Takeaways】**
- Q4 U.S. seasonality muted due to shipping delays, but 2025 guide reflects renewed momentum.
- Pharmacy channel to address Type 2 affordability, with pilot launches Q2 2025.
- Mobi pump manufacturing costs 10-15% below t:slim, contributing to 54% 2025 gross margin.
- Sigi patch pump in development, targeting 2026 launch with existing Control-IQ algorithm.
- Type 2 addressable market doubles, with 30,000+ current users without dedicated marketing.

Actual											-0.25	-0.45	-0.15	0.22	-0.08	0.06	0.09	0.16	-0.23	-0.24	-0.76	-0.25	-1.92	-0.55	-0.51	-0.46	-0.65	-0.47	-0.35	0.01	-0.6691	-0.4824	-0.3129	-0.0087
Forecast											-0.1706	-0.2397	-0.1095	0.1194	-0.1592	-0.082	0.0571	0.2096	-0.0704	0.0176	-0.0659	-0.0812	-0.5385	-0.5038	-0.4807	-0.2639	-0.7575	-0.5352	-0.4031	-0.2042	-0.6049	-0.3989	-0.3293	-0.0908
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-46.54%	-87.73%	-36.99%	+84.25%	+49.75%	+173.17%	+57.62%	-23.66%	-226.70%	-1463.64%	-1053.26%	-207.88%	-256.55%	-9.17%	-6.10%	-74.31%	+14.19%	+12.18%	+13.17%	+104.90%	-10.61%	-20.93%	+4.98%	+90.42%

TNDM

TNDM fundamentals

TNDM Q4 2025 Earnings

Earnings Call

You can ask Aime

TNDM

TNDM fundamentals

TNDM Q4 2025 Earnings

Earnings Call

TNDM Earnings Call Summary for Q4/20254:30 PM on Feb 19, 2026

TNDM Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

TNDM Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

TNDM Earnings Call Summary for Q1/20254:30 PM on Apr 30, 2025

TNDM Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime